以免疫检查点抑制剂治疗的乳腺癌的基线瘤负担和预后

相关实验视频

Updated: Jan 16, 2026

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Julia Dixon-Douglas¹, Lauren C Brown², Kate Moodie³

¹The Sir Peter MacCallum Department of Medical Oncology, University of Melbourne, Parkville, VIC 3052, Australia; INSERM Unit 981, Gustave Roussy, 114 Rue Edouard Vaillant, Villejuif 94800, France.

Breast (Edinburgh, Scotland)

|October 1, 2025

概括

基线瘤负担,通过基线瘤大小 (BTS) 和总瘤负担 (TTB) 来衡量,是用免疫检查点抑制剂 (ICI) 治疗晚期乳腺癌的显著预后生物标志物. 较低的瘤负担预测了ICI治疗的更好的结果.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
放射学放射学是一门学科.

背景情况:

免疫检查点抑制剂 (ICI) 是各种癌症的标准治疗方法,包括乳腺癌.
瘤负担的放射性评估会影响接受免疫治疗的患者的预后.
在ICI治疗的乳腺癌中,基线瘤负担的预后作用仍然不清楚.

研究的目的:

研究ICI治疗的晚期乳腺癌患者的基线瘤负担的预后意义.
确定基线瘤大小 (BTS) 和总瘤负担 (TTB) 是否与临床结果相关.

主要方法:

在2015-2020年期间接受ICI治疗的82名晚期乳腺癌患者的回顾性评估.
使用RECIST v1.1标准对BTS和TTB进行评估的瘤负担.
BTS和TTB与6个月总生存率 (OS) 和临床益处率的相关性 (CBR6).

主要成果:

较高的BTS和TTB四分位数与较差的OS (p < 0.001) 和CBR6 (p = 0.004,p = 0.002) 显著相关.
多变量分析证实了BTS/TTB和OS之间的反向关系 (p=0.035,p=0.024).
观察到瘤负担和无进展生存率之间的反向关联,但在统计学上没有显著意义.

结论:

基线瘤负担 (BTS和TTB) 是ICI治疗的晚期乳腺癌的显著预后因素.
瘤负担可以作为选择可能受益于ICI治疗的患者的生物标志物.
在基线较低瘤负担的患者中,ICI治疗似乎最有效.

关键词:

晚期乳腺癌是什么晚期乳腺癌免疫检查点抑制剂免疫检查点抑制剂预测生物标志物预测生物标志物增加了瘤负担.

更多相关视频

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.